MEI Pharma (LTS:0JW9) Construction In Progress : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is MEI Pharma Construction In Progress?

MEI Pharma Construction In Progress Historical Data

The historical data trend for MEI Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Construction In Progress Chart

MEI Pharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Construction In Progress

Get a 7-Day Free Trial

MEI Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

MEI Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

MEI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (LTS:0JW9) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma Headlines

No Headlines